Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Peters, Katherine, Gururangan, Sridharan, Sampson, John H., Marcello, Jennifer, Herndon, James E., McLendon, Roger E., Janney, Dorothea, Friedman, Allan H., Bigner, Darell D., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102498/
https://ncbi.nlm.nih.gov/pubmed/20443129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0217-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados